Skip to main content

Table 3 Effect of rh-HGF administration on survival time

From: Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

 

hazard ratio

95% CI

p value

Survival time from:

    

   onset of hepatic encephalopathy

0.20

0.03

1.45

0.08

   onset of disease

0.28

0.04

2.04

0.18

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us